Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 5/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.64 |
| ▸ | MEN1 | O00255 | 5/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | NPC1 | O15118 | 4/20 | 0.52 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.46 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.46 |
| ▸ | RELA | Q04206 | 1/20 | 0.46 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.46 |
| ▸ | IP6K1 | Q92551 | 1/20 | 0.46 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL17873963 | 0.91 | RAB9A (0.55) | RAB9ASMN1; SMN2MEN1KMT2AALDH1A1 | |
| SCHEMBL3989788 | 0.86 | MEN1 (0.53) | RAB9ASMN1; SMN2MEN1KMT2AALDH1A1 | |
| SCHEMBL3990021 | 0.86 | SMN1; SMN2 (0.53) | RAB9ASMN1; SMN2MEN1KMT2AALDH1A1 | |
| SCHEMBL212382 | 0.85 | RAB9A (0.68) | RAB9ASMN1; SMN2MEN1KMT2AALDH1A1 | |
| SCHEMBL28091339 | 0.85 | RAB9A (0.68) | RAB9ASMN1; SMN2MEN1KMT2AALDH1A1 | |
| SCHEMBL17211628 | 0.85 | LOXL2 (0.50) | RAB9ASMN1; SMN2MEN1KMT2AALDH1A1 | |
| SCHEMBL3981042 | 0.84 | SMN1; SMN2 (0.48) | RAB9ASMN1; SMN2MEN1KMT2AALDH1A1 | |
| SCHEMBL3989188 | 0.84 | LMNA (0.51) | RAB9ASMN1; SMN2MEN1KMT2AALDH1A1 | |
| SCHEMBL15774608 | 0.84 | HSD17B1 (0.47) | RAB9ASMN1; SMN2MEN1KMT2AALDH1A1 | |
| SCHEMBL3981490 | 0.84 | SMN1; SMN2 (0.46) | RAB9ASMN1; SMN2MEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230192646-A1 | DIHYDRO-CYCLOPENTA-ISOQUINOLINE DERIVATIVES | UCB Biopharma SRL (BE) | 2023-06-22 | — | — | US | claimed |
| CN-114867525-A | Dihydrocyclopentaisoquinoline derivatives | UCB生物制药有限责任公司 | 2022-08-05 | — | — | CN | claimed |
| EP-1893572-B1 | FACTOR XA INHIBITORS | MILLENNIUM PHARM INC (US) | 2016-12-14 | — | — | EP | claimed |
| US-20090298806-A1 | FACTOR XA INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. | 2009-12-03 | — | — | US | claimed |
| EP-1893572-A2 | FACTOR XA INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2008-03-05 | — | — | EP | claimed |
| US-20060100193-A1 | 5-Chloro-N-((1-(4-(2-oxopyridin-1(2H)-yl)phenyl)-1H-1,2,3-triazol-4-yl)methyl)thiophene-2-carboxamide; 5-Chloro-thiophene-2-carboxylic acid (3-p-tolyl-4,5-dihydro-isoxazol-5-ylmethyl)-amide; undesirable thrombosis inhibitor | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2006-05-11 | — | — | US | claimed |
| WO-2006002099-A2 | FACTOR XA INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2006-01-05 | — | — | WO | claimed |
| EP-3237411-B1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR INCREASING CFTR ACTIVITY | PROTEOSTASIS THERAPEUTICS INC (US) | 2023-06-07 | — | — | EP | disclosed |
| CN-114867525-A | Dihydrocyclopentaisoquinoline derivatives | UCB生物制药有限责任公司 | 2022-08-05 | — | — | CN | disclosed |
| US-20220175735-A1 | METHODS OF TREATING PULMONARY DISEASES AND DISORDERS | PROTEOSTASIS THERAPEUTICS INC (US) | 2022-06-09 | — | — | US | disclosed |
| US-20200190072-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR INCREASING CFTR ACTIVITY | PROTEOSTASIS THERAPEUTICS, INC. | 2020-06-18 | — | — | US | disclosed |
| US-10548878-B2 | Compounds, compositions, and methods of increasing CFTR activity | PROTEOSTASIS THERAPEUTICS, INC. (US) | 2020-02-04 | — | — | US | disclosed |
| US-10392372-B2 | Compounds, compositions, and methods for increasing CFTR activity | PROTEOSTASIS THERAPEUTICS, INC. (US) | 2019-08-27 | — | — | US | disclosed |
| US-20120178733-A1 | FACTOR XA INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. | 2012-07-12 | — | — | US | disclosed |
| US-20090298806-A1 | FACTOR XA INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. | 2009-12-03 | — | — | US | disclosed |
| US-7521470-B2 | Factor Xa inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2009-04-21 | — | — | US | disclosed |
| EP-1893572-A2 | FACTOR XA INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2008-03-05 | — | — | EP | disclosed |
| US-20060100193-A1 | 5-Chloro-N-((1-(4-(2-oxopyridin-1(2H)-yl)phenyl)-1H-1,2,3-triazol-4-yl)methyl)thiophene-2-carboxamide; 5-Chloro-thiophene-2-carboxylic acid (3-p-tolyl-4,5-dihydro-isoxazol-5-ylmethyl)-amide; undesirable thrombosis inhibitor | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2006-05-11 | — | — | US | disclosed |
| WO-2006002099-A2 | FACTOR XA INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2006-01-05 | — | — | WO | disclosed |
| CN-1687075-A | 3-phenyl iso-oxazole-5-aminocarbonyl substituted beta-lactam derivative and application | TIANJIN MEDICINE INST (CN) | 2005-10-26 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060100193-A1 | 5-Chloro-N-((1-(4-(2-oxopyridin-1(2H)-yl)phenyl)-1H-1,2,3-triazol-4-yl)methyl)thiophene-2-carboxamide; 5-Chloro-thiophene-2-carboxylic acid (3-p-tolyl-4,5-dihydro-isoxazol-5-ylmethyl)-amide; undesirable thrombosis inhibitor | TFPI, TFPI2, F12 | RAB9A 3528/4885SMN1; SMN2 4569/4885MEN1 3908/4885 |
| US-20090298806-A1 | FACTOR XA INHIBITORS | TFPI, F12, F11 | RAB9A 2543/4885SMN1; SMN2 4168/4885MEN1 1740/4885 |
| US-10548878-B2 | Compounds, compositions, and methods of increasing CFTR activity | CFTR, ABCB4, SCNN1B | RAB9A 840/4885SMN1; SMN2 3701/4885MEN1 4523/4885 |
| US-20120178733-A1 | FACTOR XA INHIBITORS | TFPI, F12, F11 | RAB9A 2543/4885SMN1; SMN2 4168/4885MEN1 1740/4885 |
| US-10392372-B2 | Compounds, compositions, and methods for increasing CFTR activity | CFTR, SCNN1B, SCNN1G | RAB9A 715/4885SMN1; SMN2 4744/4885MEN1 4638/4885 |
| US-20200190072-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR INCREASING CFTR ACTIVITY | CFTR, SCNN1B, SCNN1G | RAB9A 715/4885SMN1; SMN2 4744/4885MEN1 4638/4885 |
| US-20230192646-A1 | DIHYDRO-CYCLOPENTA-ISOQUINOLINE DERIVATIVES | FCER2, FCGR2A, FCGR1A | RAB9A 1222/4885SMN1; SMN2 4830/4885MEN1 4763/4885 |
| US-20220175735-A1 | METHODS OF TREATING PULMONARY DISEASES AND DISORDERS | SMPD1, ELANE, SMPD2 | RAB9A 1690/4885SMN1; SMN2 1913/4885MEN1 3829/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.